GT Biopharma

124 articles about GT Biopharma

• GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer

  11/18/2020

  GT Biopharma, Inc. an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager technology is pleased to announce Michael Handelman, CPA has been appointed Chief Financial Officer of the Company.

• GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting

  11/12/2020

  GT Biopharma, Inc.is pleased to announce its abstract "GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS)

• GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers

  10/21/2020

  GT Biopharma, Inc. an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager technology is pleased to announce the publication of "NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo" in the journal Cancers, volume 12, issue 9, page 2659;.

• GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting

  10/15/2020

  GT Biopharma, Inc. is pleased to announce its abstract "GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes and Refractory/Relapsed Acute Myeloid Leukemia Safely Drives Natural Killer Cell Proliferation At Initial Dose Cohorts" has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology Annual Meeting and Exposition

• GT Biopharma Announces Advisory Board Appointments

  10/13/2020

  GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce Dr. Samir Taneja and Dr. Philip Werthman have joined the Company's Scientific and Medical Advisory Board.

• GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics

  10/6/2020

  GT Biopharma, Inc. (OTCQB:GTBP) announced today that it had entered into a partnership agreement with Cytovance Biologics, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink").

• GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update

  9/22/2020

  GT Biopharma, Inc. an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager technology announced it completed treatment of the first patient enrolled at Dose Level 3 in its GTB-3550 TriKE™ Phase I/II clinical trial.

• GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial

  8/4/2020

  GT Biopharma, Inc. announced today it had completed treatment of patients enrolled at Dose Levels 1 and 2, and begun enrolling patients for treatment at Dose Level 3, in its GTB-3550

• GT Biopharma Announces Completion of $5.6 Million Bridge Financing

  7/22/2020

  GT Biopharma, Inc. announced today it had completed a private offering resulting in aggregate gross proceeds of approximately $5.6 million.

• GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

  5/29/2020

  GT Biopharma, Inc. an immuno-oncology company focused on NK cell engager technology.

• 

  Biopharma Industry News: Update on the Novel Coronavirus

  3/17/2020

  As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...

• GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills

  10/22/2019

  GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Drs. Jeffrey Miller, Martin Felices and Pippa Kennedy from the University of Minnesota presented research results at the recently concluded 18th meeting of the Society for Natural Immunity

• GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells

  10/22/2019

  GT Biopharma, Inc. announced that Drs. Jeffrey Miller, Martin Felices and Pippa Kennedy from the University of Minnesota presented research results at the recently concluded 18th meeting of the Society for Natural Immunity concerning a solid tumor targeting TriKE™ which demonstrates killing of non-small cell lung cancer tumor cells.

• GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

  10/3/2019

  GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology company focused on innovative treatments based on the Company's patent pending TriKE™ technology, announced today that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg

• GT Biopharma Announces HIV Trike™ Data to be Published

  9/26/2019

  GT Biopharma, Inc. announced that Dr. Jeffrey Miller and colleagues from the University of Minnesota will present research results concerning an HIV TriKE™ which directs NK cell killing at HIV-infected CD4 T-cells.

• GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics

  9/24/2019

  GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform and Multi-Target Directed Bispecific Drug Conjugate platform, announced today that it sold the rights to GTB-004 for the treatment of myasthenia gravis to DAS Therapeutics, Inc.

• GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial

  9/12/2019

  GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform and Multi-Target Directed Bispecific Drug Conjugate platform, announced today that it notified FDA that it was commencing enrollment in its first-in-human GTB-3550 Phase I/II clinical trial. 

• GT Biopharma GTB-1550

  6/13/2019

  Bloomberg discussed antibody-drug conjugates (ADC) as effective cancer therapies having the potential to replace traditional chemotherapy. ADCs are essentially a "trojan horse" therapeutics which have several advantages over traditional chemotherapy including less toxicity and higher efficacy due to a more precise targeting of cancer cells compared to non-cancer cells.

• GT Biopharma Company Update

  6/10/2019

  GT Biopharma, Inc. an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager platform and Multi-Target Directed Bispecific Drug Conjugate platform, provided an update of the company's drug development programs.

• GT Biopharma GTB-1550 Clinical Development Update

  5/30/2019

  T Biopharma, Inc. an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE) platform and Multi-Target Directed Bispecific Drug Conjugate (MTBDC) platform, provided an update with respect to the further clinical development of GTB-1550.